News and Press Releases
Press releases
Ruvidar Demonstrates 7 Year Complete Response
Press ReleaseA BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat...
Ruvidar Effective in the Treatment of Herpes
Press ReleaseRuvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025....
Theralase® Releases 2024 Annual Financial Statements
Press ReleaseTheralase® reported a slight revenue decline in 2024 but reduced net loss, advanced clinical trials for cancer and Parkinson’s treatments, showed promising results in HSV and lymphoma studies, and plans FDA resubmissions....
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® closed a non-brokered private placement, raising approximately CAD 310,200 by issuing 1,034,002 units at CAD 0.30 each. Proceeds will fund Phase II bladder cancer trials, Rutherrin® development, working capital, and general...
Theralase® Therapy Improves Motor and Non-Motor Function in Parkinson’s Patients
Press ReleaseTheralase®’s Cool Laser Therapy improved motor and non-motor functions in Parkinson’s patients in a triple-blind clinical study, showing enhanced cognition, neurovascular health, and movement, supporting its potential as a...
Theralase® Demonstrates Efficacy of Rutherrin® in Destruction of Non-Hodgkin’s Lymphoma
Press ReleaseTheralase® reported that Rutherrin®, combined with Metformin and radiation, eliminated Non-Hodgkin’s Lymphoma in an animal model. This trimodal therapy showed tumor regression and survival benefits, supporting its promise in treating...
CORRECTING AND REPLACING: Theralase® Demonstrates Effective Treatment of Herpes
Press ReleaseTheralase® validated University of Manitoba research showing Ruvidar™ is safe and effective against HSV-1. Topical treatment healed lesions in four days, supporting its potential as a herpes therapeutic and clinical candidate....
Theralase® Demonstrates Effective Treatment of Herpes
Press ReleaseTheralase® validated Ruvidar™ as safe and effective against HSV-1 in mice, with complete lesion healing in four days, supporting its potential for clinical use and advancement toward human trials....
Theralase® Releases Latest Research on Inactivation of Herpes Simplex Viruses
Press ReleaseTheralase® announced University of Manitoba research showing Ruvidar™ is more effective than acyclovir in inhibiting HSV-1 post-infection, even without light, and offers enhanced antiviral effects in combination therapy....
Theralase® Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Press ReleaseTheralase®'s bladder cancer treatment data was selected for podium presentation at the 2025 AUA Annual Meeting. Interim results show strong safety and efficacy, supporting Ruvidar™ as a breakthrough therapy option....
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
